Results 81 to 90 of about 11,081 (214)
Acta Psychiatrica Scandinavica, Volume 154, Issue 1, Page 74-88, July 2026.ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios +17 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6121-6130, July 2026.ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva +11 more
wiley +1 more source
International Journal of Preventive Medicine, 2015 Background: Drug-drug interactions (DDIs) are an emerging threat to public health and are difficult to detect. To prevent DDIs and their burden, the possible DDIs should be kept in mind.
Marjan Emzhik +4 more
doaj +1 more source
Obesity Reviews, Volume 27, Issue 7, July 2026.ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso +7 more
wiley +1 more source
Orlistat response to missense mutations in lipoprotein lipase
, 2017 The human lipoprotein lipase (LPL) is a therapeutic target for obesity, and inhibition of LPL with the approved small molecule agent orlistat has been widely used in clinic to treat obesity-related health problems such as diabetes and cardiovascular ...
Chen, Huayou +6 more
core +1 more source
Obesity Reviews, Volume 27, Issue 7, July 2026.ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao +4 more
wiley +1 more source
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease
, 2017 Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function.
Laurence Richard Solomon +7 more
core +1 more source
Brain and Behavior, Volume 16, Issue 6, June 2026.In this review, we discuss the scientific basis for how neurocognitive aging occurs after critical illness, including sepsis, trauma, and burns, and the clinical need to develop therapies to reduce inflammation, protect the blood–brain barrier, remove senescent cells, and enhance neuroplasticity.
Errin Lawrence +14 more
wiley +1 more source
Food & Nutrition Research, 2015 Background: Obesity and overweight are major public health problems. Various factors, such as daily nutritional habits, physical inactivity, and genetic, are related to the prevalence of obesity. Recently, it was revealed that the gut microflora may also
Golgis Karimi +7 more
doaj +1 more source
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Chronic Diseases and Translational Medicine, Volume 12, Issue 2, Page 100-112, June 2026.Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy +3 more
wiley +1 more source